Skip to main content

Table 4 Comparison of groups on primary and secondary outcomes at 3-month follow-up: completers only

From: A novel brief treatment for methamphetamine use disorders in South Africa: a randomised feasibility trial

 

Dependent variable

Days used

Penn total

SD work

SD Social life

SD family

CGI

HAM-A

HAM-D

Time period (reference: baseline; type III SS p-value)

0.007

< 0.001

0.011

< 0.001

< 0.001

0.001

0.002

< 0.001

 6 week follow-up

− 3.223*** (1.043)

− 9.070*** (1.908)

− 2.590** (1.050)

− 4.060*** (1.009)

− 3.383*** (0.978)

− 1.013** (0.415)

− 3.332* (1.953)

− 2.444* (1.333)

 3 month follow-up

− 2.318** (0.982)

− 12.545*** (1.785)

− 2.761*** (0.982)

− 5.580*** (0.948)

− 5.322*** (0.912)

− 1.631*** (0.396)

− 6.770*** (1.850)

− 6.073*** (1.288)

Treatment group (reference: control; type III SS p-value)

0.256

0.297

0.152

0.990

0.918

0.900

0.720

0.856

 Intervention

1.342 (1.163)

− 2.533 (2.392)

1.652 (1.128)

− 0.013

1.015)

− 0.114 (1.106)

− 0.060 (0.456)

− 1.009 (2.792)

0.305 (1.666)

Age at baseline (type III SS p-value)

0.866

0.899

0.834

0.972

0.527

0.874

0.105

0.021

 

0.010 (0.056)

0.016 (0.126)

− 0.011(0.052)

− 0.002 (0.043)

− 0.035 (0.055)

− 0.003 (0.021)

0.265 (0.159)

0.212** (0.088)

CGI-severity at baseline (type III SS p-value)

0.060

0.455

0.321

0.418

0.924

N/A

0.067

0.139

 

0.924* (0.476)

− 1.002 (1.325)

− 0.564 (0.560)

− 0.377 (0.459)

− 0.056 (0.581)

 

3.163* (1.671)

1.411 (0.932)

Number of days in past 2 weeks using meth at baseline (ttype III SS p-value)

N/A

0.991

0.173

0.050

0.138

0.009

0.564

0.925

  

− 0.003 (0.280)

0.167 (0.120)

0.201** (0.099)

0.188 (0.124)

0.107*** (0.039)

0.205 (0.353)

− 0.019 (0.198)

Time period by treatment group interaction (reference: baseline control; type III SS p-value)

0.002

0.230

0.531

0.753

0.948

0.171

0.049

0.660

 6 week follow-up Intervention

− 4.783*** (1.550)

2.041 (2.833)

− 0.603 (1.543)

− 0.249 (1.483)

0.128 (1.436)

− 1.123* (0.624)

− 5.460* (2.937)

− 1.817 (2.005)

 3 month follow-up Intervention

− 4.626*** (1.463)

4.601* (2.661)

− 1.628 (1.453)

0.802 (1.403)

0.433 (1.349)

− 0.813 (0.586)

− 6.452** (2.732)

− 0.594

(1.886)

Constant

3.232 (3.134)

27.087*** (7.127)

7.266** (2.999)

7.905*** (2.466)

8.033** (3.103)

4.353*** (0.815)

− 6.052 (8.957)

(4.983) − 1.249

Observations

113

113

111

111

111

111

111

110

Log Likelihood

− 297.348

− 367.367

− 289.208

− 280.067

− 285.397

− 196.906

− 369.688

− 320.790

Akaike Inf. Crit.

614.695

756.734

600.417

582.133

592.794

413.812

761.376

663.580

Bayesian Inf. Crit.

641.235

785.822

629.292

611.008

621.668

440.160

790.251

692.346

  1. Linear mixed-effects model; p-values entered in italic text; all other values are coefficients (standard error) unless otherwise stated
  2. *p < 0.1; **p < 0.05; ***p < 0.01